Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389607 | 0.86 | HTR2A (0.43) | HTR2AKDM1A | |
| Hydrochloric Acid SCHEMBL2388440 | 0.84 | HTR2A (0.42) | HTR2AKDM1AMAOAMAOBALOX12 | |
| SCHEMBL12745139 | 0.78 | HTR2A (0.40) | HTR2AKDM1A | |
| SCHEMBL12745112 | 0.74 | BRD4 (0.41) | — | |
| SCHEMBL27511998 | 0.74 | HTR2A (0.44) | HTR2AKDM1A | |
| SCHEMBL2390411 | 0.74 | HTR2A (0.44) | HTR2AKDM1A | |
| SCHEMBL27627297 | 0.73 | SIGMAR1 (0.41) | HTR2AKDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL2386732 | 0.72 | HTR2A (0.42) | HTR2AKDM1AMAOAMAOB | |
| SCHEMBL22515464 | 0.71 | ALOX12 (0.40) | HTR2AKDM1AMAOAMAOBALOX12 | |
| SCHEMBL10839044 | 0.71 | HTR2A (0.41) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002252-A1 | SUCCINATE DEHYDROGENASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-01-06 | — | — | US | disclosed |
| EP-2042480-B1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2013-05-01 | — | — | EP | disclosed |
| EP-2042480-A1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002252-A1 | SUCCINATE DEHYDROGENASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | SDHA, SDHB, GCDH | HTR2A 4649/4885KDM1A 974/4885MAOA 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.